Evercore ISI Group Maintains In-Line Rating for Zimmer Biomet with PT at $104.

Evercore ISI Group Maintains In-Line Rating for Zimmer Biomet with PT at $104.

Zimmer Biomet (NYSE: ZBH) has completed its acquisition of Monogram Technologies, an AI-driven orthopedic robotics company specializing in semi- and fully autonomous surgical systems. This strategic move expands Zimmer Biomet's surgical robotics portfolio, particularly in the realm of orthopedic procedures Zimmer Biomet completes acquisition of Monogram Technologies to expand orthopedic robotics portfolio^[1].

The acquisition includes Monogram's surgeon-guided, CT-based systems, which will complement Zimmer Biomet's existing Rosa Robotics platform and other navigation and mixed-reality tools. CEO Ivan Tornos commented, "By bringing Monogram into the Zimmer Biomet innovation ecosystem, we have set a bold course to become the first orthopedic company to offer a fully autonomous robotic solution complementing our current robotic and navigation offerings" Zimmer Biomet completes acquisition of Monogram Technologies to expand orthopedic robotics portfolio^[1].

Monogram's semi-autonomous total knee arthroplasty system received FDA 510(k) clearance in March 2025, with commercialization planned alongside Zimmer Biomet implants by early 2027. The company began a clinical study for its fully autonomous version in July 2025 Zimmer Biomet completes acquisition of Monogram Technologies to expand orthopedic robotics portfolio^[1]. This deal allows Zimmer Biomet to offer CT-based and imageless robotic options, further strengthening its competitive position against other orthopedic surgical robot developers like Stryker, Smith+Nephew, and Johnson & Johnson Zimmer Biomet completes acquisition of Monogram Technologies to expand orthopedic robotics portfolio^[1].

Under the merger agreement, each outstanding share of Monogram common stock converted into $4.04 in cash plus non-tradeable contingent value rights worth up to $12.37 if development, regulatory, and revenue milestones are met by 2030. Monogram shares stopped trading on Nasdaq before the market opened on October 7 and will be delisted Zimmer Biomet completes acquisition of Monogram Technologies to expand orthopedic robotics portfolio^[1].

In a separate development, Evercore ISI Group has maintained its in-line rating for Zimmer Biomet with a price target (PT) of $104, reflecting the company's strategic growth initiatives and the potential benefits of the Monogram acquisition .